{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:46:54Z","timestamp":1775227614614,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"This work was supported by the Dr. Adolph and Klara Brettler Endowment Fund in Urology, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06314-3","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T13:52:36Z","timestamp":1775224356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intermediate-term oncological and functional outcomes of neoadjuvant 177-Lu-PSMA-I&amp;T radionuclide treatment followed by radical prostatectomy"],"prefix":"10.1007","volume":"44","author":[{"given":"Michael","family":"Frumer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisha","family":"Fredman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxim","family":"Yakimov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Kedar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Baniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Groshar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Bernstine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shay","family":"Golan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"issue":"2","key":"6314_CR1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.juro.2007.03.105","volume":"178","author":"O Yossepowitch","year":"2007","unstructured":"Yossepowitch O, Eggener SE, Bianco FJ Jr., Carver BS, Serio A, Scardino PT, Eastham JA (2007) Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 178(2):493\u2013499 discussion 9","journal-title":"J Urol"},{"key":"6314_CR2","doi-asserted-by":"publisher","unstructured":"Spena G, Moretti TB, D\u00e1vila FS, Dos Anjos G, Khan I, Calace FP, Aveta A, Pandolfo SD, Tufano A, Izzo A, Farias A, Perdon\u00e0 S, Maes K (2024) Ga68-PSMA PET for lymph node staging in intermediate and high-risk prostate cancer patients undergoing robotic assisted radical prostatectomy. Minerva Urol Nephrol. 76(4):467\u2013473. https:\/\/doi.org\/10.23736\/S2724-6051.24.05736-7. PMID: 39051893","DOI":"10.23736\/S2724-6051.24.05736-7"},{"key":"6314_CR3","doi-asserted-by":"crossref","unstructured":"Eastham JA, Heller G, Halabi S, Monk JP 3rd, Beltran H, Gleave M, Evans CP, Clinton SK, Szmulewitz RZ, Coleman J, Hillman DW, Watt CR, George S, Sanda MG, Hahn OM, Taplin ME, Parsons JK, Mohler JL, Small EJ, Morris MJ (2020) Cancer and Leukemia Group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer. J Clin oncology: official J Am Soc Clin Oncol 38(26):3042\u20133050","DOI":"10.1200\/JCO.20.00315"},{"issue":"6","key":"6314_CR4","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1097\/JU.0000000000001632","volume":"205","author":"RR McKay","year":"2021","unstructured":"McKay RR, Berchuck J, Kwak L, Xie W, Silver R, Bubley GJ, Chang PK, Wagner A, Zhang Z, Kibel AS, Taplin ME (2021) Outcomes of post-neoadjuvant intense hormone therapy and surgery for high risk localized prostate cancer: results of a pooled analysis of contemporary clinical trials. J Urol 205(6):1689\u20131697","journal-title":"J Urol"},{"key":"6314_CR5","unstructured":"EAU Guidelines (2023) Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6. Arnhem, the Netherlands: EAU Guidelines Office"},{"issue":"1","key":"6314_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/JU.0000000000002758","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, Eggener S, Horwitz EM, Kane CJ, Kirkby E, Lin DW, McBride SM, Morgans AK, Pierorazio PM, Rodrigues G, Wong WW, Boorjian SA (2022) Clinically localized prostate cancer: AUA\/ASTRO guideline, part II: principles of active surveillance, principles of surgery, and follow-up. J Urol 208(1):19\u201325","journal-title":"J Urol"},{"key":"6314_CR7","doi-asserted-by":"publisher","unstructured":"Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW (2016) Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts. Int J Mol Sci 17(5):736. https:\/\/doi.org\/10.3390\/ijms17050736","DOI":"10.3390\/ijms17050736"},{"issue":"12","key":"6314_CR8","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, P\u00e9rez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385(12):1091\u20131103","journal-title":"N Engl J Med"},{"issue":"2","key":"6314_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.euo.2022.09.002","volume":"6","author":"S Golan","year":"2023","unstructured":"Golan S, Frumer M, Zohar Y, Rosenbaum E, Yakimov M, Kedar D, Margel D, Baniel J, Steinmetz AP, Groshar D, Domachevsky L, Bernstine H (2023) Neoadjuvant (177)Lu-PSMA-I&T radionuclide treatment in patients with high-risk prostate cancer before radical prostatectomy: a single-arm phase 1 trial. Eur Urol Oncol 6(2):151\u2013159","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"6314_CR10","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0022-5347(05)64548-X","volume":"168","author":"M Menon","year":"2002","unstructured":"Menon M, Shrivastava A, Tewari A, Sarle R, Hemal A, Peabody JO, Vallancien G (2002) Laparoscopic and robot assisted radical prostatectomy: establishment of a structured program and preliminary analysis of outcomes. J Urol 168(3):945\u2013949","journal-title":"J Urol"},{"issue":"5","key":"6314_CR11","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","volume":"148","author":"MJ Barry","year":"1992","unstructured":"Barry MJ, Fowler FJ Jr., O\u2019Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148(5):1549\u20131557 discussion 64","journal-title":"J Urol"},{"issue":"6","key":"6314_CR12","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","volume":"49","author":"RC Rosen","year":"1997","unstructured":"Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A (1997) The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49(6):822\u2013830","journal-title":"Urology"},{"key":"6314_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-017-0233-1","volume-title":"The measurement and valuation of health status using EQ-5D: a European perspective","author":"R Brooks","year":"2003","unstructured":"Brooks R, Rabin R, de Charro F (2003) The measurement and valuation of health status using EQ-5D: a European perspective. Kluwer, Dordrecht"},{"issue":"7","key":"6314_CR14","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/bju.12258","volume":"112","author":"I Geraerts","year":"2013","unstructured":"Geraerts I, Van Poppel H, Devoogdt N, Van Cleynenbreugel B, Joniau S, Van Kampen M (2013) Prospective evaluation of urinary incontinence, voiding symptoms and quality of life after open and robot-assisted radical prostatectomy. BJU Int 112(7):936\u2013943","journal-title":"BJU Int"},{"issue":"11","key":"6314_CR15","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jama.2017.1652","volume":"317","author":"RC Chen","year":"2017","unstructured":"Chen RC, Basak R, Meyer AM et al (2017) Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. JAMA 317(11):1141\u20131150. https:\/\/doi.org\/10.1001\/jama.2017.1652","journal-title":"JAMA"},{"issue":"3","key":"6314_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/cncr.31833","volume":"125","author":"D Sundi","year":"2019","unstructured":"Sundi D, Tosoian JJ, Nyame YA, Alam R, Achim M, Reichard CA, Li J, Wilkins L, Schwen Z, Han M, Davis JW, Klein EA, Schaeffer EM, Stephenson AJ, Ross AE, Chapin BF (2019) Outcomes of very high-risk prostate cancer after radical prostatectomy: validation study from 3 centers. Cancer 125(3):391\u2013397","journal-title":"Cancer"},{"issue":"3","key":"6314_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","volume":"85","author":"RS Eapen","year":"2024","unstructured":"Eapen RS, Buteau JP, Jackson P et al (2024) Administering [177Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-centre, single-arm, phase 1\/2 study. Eur Urol 85(3):217\u2013226. https:\/\/doi.org\/10.1016\/j.eururo.2023.08.026","journal-title":"Eur Urol"},{"issue":"3","key":"6314_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/CU9.0000000000000242","volume":"18","author":"X Zhang","year":"2024","unstructured":"Zhang X, Ma Z (2024) Head-to-head comparison of PSMA PET\/CT and mpMRI for detecting biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Curr Urol 18(3):177\u2013184","journal-title":"Curr Urol"},{"key":"6314_CR19","doi-asserted-by":"publisher","first-page":"109556","DOI":"10.1016\/j.ejrad.2021.109556","volume":"136","author":"J Morawitz","year":"2021","unstructured":"Morawitz J, Kirchner J, Lakes J, Bruckmann NM, Mamlins E, Hiester A, Aissa J, Loberg C, Schimm\u00f6ller L, Arsov C, Antke C, Albers P, Antoch G, Sawicki LM (2021) PSMA PET\/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: comparison of detection rates and therapeutic implications. Eur J Radiol 136:109556","journal-title":"Eur J Radiol"},{"issue":"7","key":"6314_CR20","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/RLU.0000000000001197","volume":"41","author":"C Bluemel","year":"2016","unstructured":"Bluemel C, Krebs M, Polat B, Linke F, Eiber M, Samnick S, Lapa C, Lassmann M, Riedmiller H, Czernin J, Rubello D, Bley T, Kropf S, Wester HJ, Buck AK, Herrmann K (2016) 68Ga-PSMA-PET\/CT in patients with biochemical prostate cancer recurrence and negative 18F-choline-PET\/CT. Clin Nucl Med 41(7):515\u2013521","journal-title":"Clin Nucl Med"},{"key":"6314_CR21","doi-asserted-by":"crossref","unstructured":"Bakht MK, Derecichei I, Li Y, Ferraiuolo RM, Dunning M, Oh SW, Hussein A, Youn H, Stringer KF, Jeong CW, Cheon GJ, Kwak C, Kang KW, Lamb AD, Wang Y, Dong X, Porter LA. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr Relat Cancer. ;26(2):131\u2013146. doi: 10.1530\/ERC-18-0226.","DOI":"10.1530\/ERC-18-0226"},{"key":"6314_CR22","doi-asserted-by":"crossref","unstructured":"Tao H, Wu F, Li R, Du X, Zhu Y, Dong L, Pan J, Dong B, Xue W (2018) Efficacy and predictive factors analysis of androgen deprivation plus novel hormone therapy as neoadjuvant treatment for high-risk prostate cancer. Prostate. 2025;85(2):198\u2013206","DOI":"10.1002\/pros.24817"},{"issue":"3","key":"6314_CR23","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1007\/s00259-024-06959-5","volume":"52","author":"A G\u00e4ble","year":"2025","unstructured":"G\u00e4ble A, Dierks A, Rinscheid A, Patt M, Wienand G, Pfob CH, Kircher M, Fukushima K, Nikoli\u0107 AA, Enke JS, Janzen T, Steinestel J, Kempter H, Trepel M, Weckermann D, Lapa C, Bundschuh RA (2025) Experience of rescue therapy with [(177)Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [(177)Lu]Lu-PSMA-I&T. Eur J Nucl Med Mol Imaging 52(3):970\u2013978","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"6314_CR24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ijrobp.2022.07.016","volume":"115","author":"L Hammer","year":"2023","unstructured":"Hammer L, Jiang R, Hearn J, Lashbrook J, Mitchell A, Daignault-Newton S, Dess RT, Jackson WC, Reichert Z, Alumkal JJ, Kaffenberger S, George A, Montgomery J, Salami SS, Morgan TM, Miller D, Wittman D, Hollenbeck B, Mehra R, Davenport MS, Sun Y, Schipper M, Palapattu G, Spratt DE (2023) A phase I trial of neoadjuvant stereotactic body radiotherapy prior to radical prostatectomy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 115(1):132\u2013141","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"6314_CR25","doi-asserted-by":"publisher","first-page":"25712","DOI":"10.1038\/s41598-024-77889-3","volume":"14","author":"S Wu","year":"2024","unstructured":"Wu S, Hu W, Chen M, Xiao X, Liu R (2024) A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617. Sci Rep 14(1):25712","journal-title":"Sci Rep"},{"issue":"10338","key":"6314_CR26","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","volume":"399","author":"A Pollack","year":"2022","unstructured":"Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, Wefel JS, Martin AG, Michalski JM, Angyalfi SJ, Lukka H, Faria SL, Rodrigues GB, Beauchemin MC, Lee RJ, Seaward SA, Allen AM, Monitto DC, Seiferheld W, Sartor O, Feng F, Sandler HM (2022) The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet 399(10338):1886\u20131901","journal-title":"Lancet"},{"issue":"1","key":"6314_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2024.09.009","volume":"87","author":"WL Ong","year":"2025","unstructured":"Ong WL, Romero T, Roy S, Nikitas J, Joseph D, Zapatero A, Malone S, Morgan SC, Steinberg ML, Valle LF, Zaorsky NG, Martin Ma T, Rettig MB, Nickols N, Jiang T, Reiter RE, Eleswarapu SV, Maldonado X, Sun Y, Nguyen PL, Millar JL, Martin JM, Spratt DE, Kishan AU (2025) Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium. Eur Urol 87(1):49\u201357","journal-title":"Eur Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06314-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06314-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06314-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T13:52:39Z","timestamp":1775224359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06314-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6314"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06314-3","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the institutional review board (approval number 0315-19-RMC) and the Ministry of Health. All patients provided written informed consent before enrolling in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"274"}}